



Exjade[®] (deferasirox) – First-time generic

- On March 22, 2019, [Teva Pharmaceuticals launched](#) an [AB-rated](#) generic version of Novartis' [Exjade \(deferasirox\)](#) tablets for oral suspension.
- Exjade is approved for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older, and for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia syndromes and with a liver iron concentration of at least 5 mg of iron per gram of liver dry weight and a serum ferritin greater than 300 mcg/L.
- Deferasirox is also available as brand oral sprinkle granules and tablets ([Jadenu[®]](#)).
 - Jadenu carries the same indications as Exjade.
- Exjade carries a boxed warning for renal failure, hepatic failure, and gastrointestinal hemorrhage.
- According to IQVIA data, Exjade had annual sales of \$134 million in the U.S. as of December 2018.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.